History of other previous cancer that would interfere with the determination of safety or efficacy
Previous therapy with anthracyclines or taxanes for any malignancy
Patients must not have any unresolved wounds from previous surgery
If a patient has progressed in previous areas of primary disease that received definitive doses of radiation, these patients would require re-irradiation in previous high dose anatomic areas and are not eligible for this study.
Previous radiotherapy to the scalp, cranium, brain, or skull base and radiation-induced meningiomas
Previous exposure to pralatrexate.
Patient has had previous treatment with the study drug or other Wilms' tumor 1 (WT1)-related immune therapy
Receipt of previous approved or investigative immune modulatory agent within 28 days of receiving the first dose of treatment;
Systemic treatment with interferon (IFN)-? within the previous 6 months.
Has received pegzilarginase as part of any previous therapy
Previous treatment with venetoclax or other B-Cell Lymphoma 2 (BCL-2) inhibitor OR previous treatment with daratumumab or other anti-CD38 therapy.
Failed previous HSC collections or collection attempts.
Presence of any remaining toxicities due to previous chemotherapy
Previous treatment with Apatinib.
Recovery from significant toxicities from previous therapies and sufficient time since last dose of previous therapy
Received previous therapy for malignancy within 21 days
Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study
History of previous chemotherapy
Any previous autologous EBV specific T cell treatment.
Previous treatment for ALL, except for prior steroids and/or hydroxyurea
Patients who have had previous treatment with tivozanib are excluded
Patients who have had previous treatment with nintedanib
The disease should be progressing/relapsed during or after the previous treatment.
Previous therapy with anthracyclines or taxanes for any malignancy.
Chemotherapy treatment within the previous 12 months
Previous therapy with anthracyclines or taxanes for any malignancy
Previous treatment in the target tumor area
Previous treatment with ixazomib, or participation in a study with ixazomib whether treated with ixazomib or not
No previous regional treatment (includes surgery, radiation or liver-directed arterial or ablative therapy)
Presence of active lymphoma or active PTLD, based on imaging performed within the previous 3 months.
Relapse or progression following previous autologous EBV specific T cell treatment.
Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study.
Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within previous 24 weeks
Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study
Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study
relevant toxicity from previous treatment
Have not recovered to ? Grade 1 toxicity from previous anticancer treatments or previous IPs.
Previous or concurrent treatment with selective estrogen receptor modulator (SERM) and/or hormonal replacement therapy within 3 months of the study
Previous treatment with enzalutamide (MDV3100)
No systemic treatment in the previous 28 days.
Previous immunization against CT7, MAGE-A3, other cancer-testis antigens, or WT1
Patients with previous treatment with abraxane
Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment.
Previous exposure to gemcitabine will only be allowed if there is no residual toxicity from previous treatments. Toxicity must be graded as 0 or 1 prior to study
Previous intrapleural therapy for MPE on the same side
History of previous enrollment in Studies NCT02993523 or NCT03069352.
Previous participation in a liposome bupivacaine study.
No previous systemic treatment for cGVHD (including extracorporeal photopheresis [ECP])
Previous treatment with a pyrrolobenzodiazepine (PBD)-based drug Additional exclusion criteria for the SC-003 and ABBV-181 combination treatment regimen:
14 day wash-out period from any previous chemotherapy, targeted therapy or radiotherapy, 21 day washout period from previous immunotherapy
No previous HIPEC
Previous serious adverse reactions to smallpox vaccination
Any evidence of mucositis/stomatitis or previous history of severe (?Grade 3) mucositis from prior therapy.
Previous investigational antiandrogens (e.g., apalutamide, enzalutamide, BMS-641988).
Had previous exposure to Betafectin® or Imprime PGG
Patient has received any previous intravesical therapy for bladder cancer- chemotherapy, immunotherapy, or previous exposure to Qapzola in the last 3 years
Dispositioned to single modality photon radiotherapy (i.e. no chemotherapy or previous therapeutic intent surgery).
Myocardial infraction (MI) within the previous 6 months
Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment
Patients who experienced a severe systemic reaction or side-effect as a result of a previous vaccination with vaccinia
Active inflammatory gastrointestinal disease or previous gastric resection or lap band
Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study
Previous enrollment in this study, followed by withdrawal for any reason.
Previous treatment with talimogene laherparepvec or any other oncolytic virus
Myocardial Infraction (MI) within the previous 6 months
Any previous local treatment of the prostate (i.e. radiation)
A history of neurological complications due to past poliovirus (PV) infection would imply previous virus replication in the central nervous system (CNS); based on animal studies, previous exposure to poliovirus administered intracerebrally can reduce subsequent virus replication in the CNS
Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter the study
COHORT 1 (WITH SORFENIB): No previous systemic therapy including sorafenib or chemotherapy treatment; previous TACE and local treatments are permitted
Previous assignment to treatment during this study; patients permanently withdrawn from study participation will not be allowed to re-enter the study
Patients may not have undergone previous treatment with lomustine.
At least 4 weeks since any previous treatment for cancer
Tumor recurrence after previous treatment, which must have included at least radiation therapy and one cytotoxic chemotherapy; there is no limit on number of previous recurrences or lines of treatment
Previous treatment information (name of agent, treatment starting date, and date of progression) must be available for review
Patients with a previous history of neurological complications due to polyoma virus (PV) infection
Previous enrolment in this trial
Previous history of grade 3 or worse drug-induced QTc prolongation requiring treatment withdrawal
Persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy
Previous use of TAS-114, S-1, and 5-FU drugs;
Patient with previous administration of immunosuppressive therapy for SAA
Previous TSEB therapy with total dose > 20 Gy
Patients not previously treated for their FL, including any previous treatment for FL under clinical trials except localized radiation therapy for previous limited stage disease.
For Phase 1a LY3300054 monotherapy or combination therapy, previous immunotherapy is acceptable if the following criteria are met:
Previous chemotherapy
Gastrointestinal surgery within the previous 3 months
Previous treatment with AKT inhibitors (e.g., ARQ 092, MK-2206, GSK2141795, AZD5363)
Patient must have received one and only one previous course of radiation to the brain, delivered at 1.5 - 2.5 Gy/fraction, one fraction per day
Previous CNS surgery within 2 weeks of treatment, with the exception of biopsy
Previous exposure to toll-like receptor (TLR) agonist therapy
History of a previous treated cancer except for the following:
Previous serious adverse reactions to smallpox vaccination
Patients must have relapsed after at least 1 but at most 3 prior lines of therapy, including rituximab-based immunochemotherapy and alkylating agents. A previous regimen is defined as one of the following: at least 2 months of single-agent therapy; at least 2 consecutive cyclesof polychemotherapy; autologous transplant; radioimmunotherapy. Previous exposure to other PI3Ki is acceptable provided there is no resistance.
Previous therapy with antiandrogens within 4 weeks
Previous radiation therapy with anything other than standard radiation therapy (such as previous stereotactic radiosurgery) or previous treatment with an immune checkpoint inhibitor (i.e., nivolumab, pembrolizumab, ipilimumab)
Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study. Patients who progress on placebo are specifically allowed to enroll on the treatment arm of the study if they meet all other entry criteria
Previous treatment with farletuzumab or other folate receptor targeting agents
No previous treatment with vandetanib; previous or ongoing treatment with metformin is allowed
A \washout\ period of at least 14 days from last previous cytotoxic chemotherapy will be required prior to starting treatment on this protocol; no “washout” period will be required for previous bcr-abl TKI therapy given with the aforementioned previous chemotherapy cycles; hydroxyurea and corticosteroids may be given as bridge therapy up until 24 hours prior to initiating protocol treatment
Must not have received any tumor vaccines within previous six weeks
Previous treatment with AKT inhibitors (e.g., MK-2206, GSK2141795, AZD5363)
Previous radioimmunotherapy. Previous antibody-based therapy is allowed as long as ? 28 days has elapsed from last dose to study treatment.
Previous treatment with ifosfamide and Grade greater than or equal to 3 nephrotoxicity or encephalopathy (Cohorts 3A and 3B).
No limit in the number of previous surgical resections
Histologically or cytologically documented MDS of any risk group that has failed previous therapy (therapy failure is defined as patients who have been sufficiently treated with previous agents without response in the opinion of the treating physician, or whose disease has progressed or relapsed while on a hypomethylating agent)
Previous biliary drainage by ERCP/PTC
Previous chemotherapy for this tumor
Any previous BMT must have occurred at least 3 months prior to start of conditioning
Patients who have received >= 2 cycles of multiagent chemotherapy within the 3 months previous to UCBT; patients who have had previous autologous transplant within 12 months of UCBT are excluded regardless of history of recent treatment
Patient has had previous treatment with poziotinib.
Previous treatment with ixazomib, or participated in a blinded study with ixazomib
Previous exposure to vinorelbine (applicable for Cohort 1 triplet combination only)
Previous systemic or local treatment for the new primary breast cancer currently under investigation (including surgery, radiotherapy, cytotoxic and endocrine treatments); prior treatment for previous breast cancer or other neoplasms is allowed as long as it was completed at least 1 year prior to inclusion into this trial.
Patients who tolerated previous administration with TMZ
Previous treatment for NHL
Previous selinexor exposure
Previous or current treatment with mitotane or other antineoplastic drugs for ACC
Previous radiotherapy of the tumor bed (for ACC).
Previous radiation treatment in either breast at any time
Previous intravesical immunotherapy less than 3 months before study entry; Note: if a patient is eligible for the study but has had intravesical immunotherapy within the past 3 months, they can enroll in the study and initiation of treatment of the drug will be delayed until a minimum of 90 days has passed since the previous treatment
No more than 6 calendar months from last dose of previous anti-EGFR mAb treatment to date of consent for this trial (regardless of the line of therapy in which it was used)
Additional Exclusion Criteria for Subjects Assigned to Treatment B: Unacceptable AEs from previous bortezomib treatment; Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain from previous bortezomib treatment; Intolerance or contraindications to anti-viral prophylaxis.
Prior toxicity to anti-FGFR-directed or anti-PI3K-directed therapies leading to treatment discontinuation (previous exposure is allowed in other circumstances).
History of prior breast cancer-specific therapy within the previous 2 years (chemotherapy, radiation, anti-HER2 agents, endocrine agents, everolimus, CDK4-6 inhibitors); previous unilateral radiation of the contralateral side in women scheduled for mastectomy is allowed; study gel will be applied to both breasts
Treatment with corticosteroids other than physiological replacement within the previous week or treatment with immunosuppressive medication within the previous week.
Previous treatment with talimogene laherparepvec or any other oncolytic virus
Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment
BLADDER: The patient must be systemic treatment naive, previous intra-vesicle therapy is allowed
Previous assignment to treatment during this study; patients permanently withdrawn from study participation will not be allowed to re-enter the study
Has an ongoing or previous history of spontaneous intratumoral hemorrhage.
Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study
Previous treatment with talimogene laherparepvec (T-VEC) or any other oncolytic virus
Previous therapy with pazopanib
Previous treatment with TAS-102 or TMZ
Previous first line treatment with at least standard dose of radiotherapy (total dose >= 54 Gy) and temozolomide
Any previous treatment with vosaroxin
Previous exposure to vandetanib
Individuals with a history of a previous malignancy are ineligible; also, exposure to previous anti-neoplastic treatment may alter the ability to tolerate or respond to the agents utilized in this protocol; exception: individuals with a previous malignancy treated with surgery only (no chemotherapy or radiotherapy) more than 5 years prior to registration may be enrolled
Previous sphincterotomy or bilio-enteric anastomosis
Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study
Previous history of intravesical therapy allowed
Previous treatment with eribulin mesylate
Previous treatment with genetically engineered GD2-CAR T cells; previous vaccine therapy, anti-GD2 mAb therapy or therapy with other genetically engineered T cells is not an exclusion criteria
Previous systemic cancer therapy for myeloma
Patient who has received previous chemotherapy or radiation therapy in the previous 3 months, except for empiric initial intrathecal administration at diagnosis; rituximab or steroid administration is not an exclusion criterion
No previous chemotherapy
All previous intravenous therapy administered outside of the National Institute of Health (NIH) Clinical Center must be completed at least 2 weeks prior to study entry, with recovery to =< non-hematologic grade 2 toxicity of previous therapy
No previous exposure to any formulation of interferon
No previous exposure to any formulation of pegylated interferon
They have had previous I-131 MIBG therapy
At least 4 weeks since any previous treatment for cancer
Previous chemotherapy for this tumor
Previous chemotherapy or chemoradiotherapy outside of the InPACT trial
Recovery from significant toxicities from previous therapies and sufficient time since last dose of previous therapy
Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances
>2 previous systemic anti-neoplastic regimens for CCA.
History of listeriosis or previous treatment with a listeria-based immunotherapy
Previous therapy with:
Previous cytotoxic, cytostatic, hormonal, biological or immunological treatment (ESA with or without G-CSF and iron chelating therapy and hydroxyurea are allowed under certain conditions, see exclusion criterion #5) or biologic treatment for AML.
Patients who have had previous treatment with:
Previous cancer treatment contraindicates this protocol therapy.
Previous treatment with Samarium-153 or Strontium-89.
Previous treatment with Samarium-153, Strontium-89, Rhenium-186 or Radium-223 within 6 months of starting (i.e., Cycle 1 Day 1) EC1169
The subject with a previous history of a non-invasive carcinoma is eligible if he/she has had successful curative treatment any time prior to Screening.
Previous significant urinary obstructive symptoms
Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study.
Previous antiangiogenic treatment
More than one previous treatment line with erlotinib, gefitinib or afatinib
Previous first line treatment with at least standard dose of radiotherapy (total dose >= 54 gray [Gy]) and temozolomide
Previous experimental therapy with SS1 moiety, murine or chimeric antibodies (human and humanized antibodies are allowed)
Participants must have never received previous R-CHOP treatment
Previous therapy for metastatic gastroesophageal cancer; previous perioperative chemotherapy is allowed as long as the duration without treatment has been greater than 6 months
Previous systemic chemotherapy for MPM
Previous treatment with SB-485232 or ofatumumab
Subject has had previous treatment with ART-123.
Less than 6 months since the end of previous radiation
Patients who have received systemic treatment with IFN-? within the previous 6 months prior to enrolling into this study.
Patients must have not received previous treatment with any of the study medications or similar drugs
Has undergone a colectomy procedure in the previous two months
Has an emergent infection related to a previous colectomy procedure
Persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy
Have participated in a previous study of duvelisib, and:
Previous serious adverse reactions to smallpox vaccination
Previous treatment with any other compound that targets CD40
Have received previous systemic therapy with ramucirumab
The subject with a previous history of a noninvasive carcinoma is eligible if in the opinion of the investigator he/she has had successful curative treatment any time prior to Screening and requires no further therapy for the malignancy.
Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study
Previous exposure to either fluorouracil (5-FU) or capecitabine at a systemic dose except for use in concurrent chemoradiation
Subjects who have not recovered to Grade 0 or 1 toxicity from previous anti-cancer treatments or previous investigational agents.
Patients who have had previous treatment with selinexor
Patients who have been resistant to previous TKI therapy are not eligible
Treatment naïve or have failed on previous treatment for PRCC. Previous treatments may include: targeted therapy (i.e. sunitinib, sorafenib, bevacizumab, pazopanib, temsirolimus, and everolimus), traditional immunotherapy (i.e. interferon-a, Interleukin-2), chemotherapy or a combination of chemoimmunotherapy.
Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study
Previous enzalutamide therapy
Previous laryngeal surgery
Previous laser therapy within one year prior to protocol treatment
Previous treatment with T-DM1 at any time; or previous treatment with any small molecule HER2 inhibitors including (but not limited to) lapatinib, neratinib, or afatinib within the last 4 weeks prior to initiation of study therapy.
Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
Previous treatment with MLN1117 and/or MLN0128; previous treatment with dual mTORC1/2 or dual PI3K-mTOR inhibitors
Previous serious adverse reactions to smallpox vaccination
Previous adverse reactions to smallpox vaccination
Previous assignment to treatment during this study
Previous treatment with any HER2-directed therapy, at any time, for any duration
Previous exposure to any investigational treatment within 30 days before the first dose of study treatment
Patient who has had any prior radiotherapy to the treatment site(s); as in, definitive therapy for lesion of interest; field overlap from previous treatment is permitted at the discretion of the treating investigator
Previous treatment with cytotoxic chemotherapy, immunotherapy, radiotherapy or other lymphoma specific therapy within 14 days before the screening visit or patient has not recovered from side effects of previous lymphoma-specific therapy.
Treatment with BT062 in previous studies
Participants who relapsed from their previous treatment(s) but were not refractory to any previous treatment.
Previous treatment with isolated hepatic perfusion
Previous treatment with agents that target the IGF receptor
Previous exposure to hepatitis A or B vaccines
Previous treatment with dacarbazine (DTIC) or TMZ
Any prior therapy for lymphoma within the previous 2 weeks for standard treatments and within 4 weeks for experimental therapies unless the patient has recovered from the nadir of the previous treatment to a level that meets the inclusion criteria
Patients who have received treatment with IFN-? within the previous 6 months prior to enrollment.
Had previous exposure to Betafectin® or Imprime PGG
No previous radiation, cytotoxic chemotherapy, radio surgery, or investigational treatment directed at the brain tumor at any time; no limit on number of previous surgical procedures of this tumor
Patients may not participate in this trial if the conditions for continuing treatment in the previous AG-013736 protocol are not met
Previous chemotherapy for any malignancy including temozolomide, dacarbazine (DTIC) or prior nitrosourea
Patients on previous treatment with carboplatin.
Patients who have received previous chemotherapy for the treatment of metastatic or unresectable gastric or GEJ adenocarcinoma are ineligible; patients who have received previous pre- or post-operative chemotherapy or chemoradiation are ineligible if therapy was completed less than 6 months prior to study registration; patients must have recovered from adverse events from any previous therapy
Previous ZD6474 treatment
Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study.
Patients who have had previous treatment with topotecan
Patients with previous exposure to brentuximab pre-transplant are eligible for the study
Residual AEs >Grade 2 from previous treatment
Residual AE from previous treatment > Grade 1
Previous use of interferon, ixazomib or bortezomib
Previous treatment with sunitinib.
Previous exposure to PNT2258.
Have had a previous extra pleural pneumonectomy (EPP).
Previous exposure to BTKi therapy and meets at least one of the below criteria:
Metastatic disease that has progressed on previous therapy or previous therapy was not tolerated
Previous radiation treatment to the tumor
Residual relevant toxicity resulting from previous therapy
Has had previous exposure to Betafectin® or Imprime PGG;
Have received previous treatment with ramucirumab or LY2875358, except for participants enrolled in cohort B1 (Gastric or GEJ adenocarcinoma) and B4 (non- small cell lung cancer) who may have received previous ramucirumab treatment.
Previous use of mitoxantrone and etoposide combination therapy within the preceding 180 days of screening
Previous cardiac operation.
Patient has had previous treatment with the study drug or other WT1-related vaccine therapy.
No previous treatment with chemotherapy for AML, other than hydroxyurea; previous treatment with hypomethylating agents is acceptable
Previous treatment defined as follows:\r\n* Previous participation in this study\r\n* Previous radiotherapy to the site of vertebroplasty prior to study enrollment\r\n* Samarium therapy at any previous time
Previous treatment with agents targeting the insulin like growth factor (IGF) signalling pathway.
Previous treatment with nintedanib
Chemotherapy treatment within the previous 12 months.
Have an interval from previous neurotoxic platinums of less than 6 months and/or from previous other neurotoxic drugs less than 3 months (e.g, taxanes) unless reasonably recovered from all grades of neurotoxicity as judged by the investigator
Previous systemic therapy to treat small-cell lung cancer (SCLC). Subjects with recurrent or progressive limited-stage SCLC after previous systemic treatment are not eligible for study participation.
Have not recovered to ? Grade 1 toxicity from previous anticancer treatments or previous investigational agents
Must have had no previous systemic anti-cancer treatment, though previous loco-regional therapy is allowed: a. Prior treatment with any of the following is allowed: trans-arterial embolization, trans-arterial chemo-embolization, percutaneous ethanol injection, radio-embolization, radio-frequency ablation, or other ablation techniques.
Evidence of residual disease either by increased blasts count (> 5%) or persistence of previous known cytogenetics abnormalities
Previous treatment with vemurafenib
Concurrent or previous treatment with inhibitors of DLL4
Any history of CVA or TIA in previous six months
Previous treatment with AKT inhibitors
Unmanageable toxicity, an adverse event, progression of disease, or withdrawal of consent as reason for discontinuing treatment from previous sponsor-initiated siltuximab study
Had previous open thoracotomy procedures
> 4 weeks since discontinuation of tivozanib treatment on a previous protocol
Any previous BMT must have occurred at least 3 months prior to start of conditioning
No previous allogeneic BMT (syngeneic BMT permissible)
Any infectious disease requiring treatment at the time of enrolment or within the previous 2 weeks.
Previous treatment with ofatumumab.
Patients with previous exposure to trabectedin
Previous chemo within 2 wks
Previous chemo within 2 wks
Previous treatment with ofatumumab.
Permanent discontinuation of lapatinib in the previous study due to intolerance or treatment failure.
For phase I, any solid tumors, including lymphoma, that progressed or were stable as best response on at least one previous therapy but no more than two previous cytotoxic therapies and are evaluable
The subject has a treatment related serious adverse event that remains unresolved or unstable or had pazopanib permanently stopped in a previous study because of intolerate or because it was unsuccessful in treating your cancer
Previous treatment with talimogene laherparepvec or any other oncolytic virus
Relative contraindications: presence of bleeding disorders; distortion of anatomy due to local injury or deformity; previous long-term venous catheterization; history of vasculitis; previous injection of sclerosis agents; previous radiation therapy
Previous treatment with lenvatinib mesylate (E7080)
Previous treatment with tocilizumab (TCZ)
Patients who have had previous treatment with pazopanib or topotecan
Have smoked daily or nearly every day in the previous 6 months up to the date of surgical consult AND have smoked at least one puff in the previous 7 days
Previous use of light therapy to alleviate fatigue or depressive symptoms
Previous radiation in the operated breast
Previous exposure to enzalutamide
Any previous treatment for vulvar HSIL within 4 weeks prior to screening;
Previous cancer genetic testing or counseling, or prior germline multigene panel testing
Previous use of light therapy to alleviate fatigue or depressive symptoms
Patients who have received previous treatment with ionizing radiation
Patients who have a history of previous gastric or duodenal surgery
Participated in a previous elotuzumab protocol (including, but not limited to HuLuc63-1703, CA204007, CA204009, or CA204011) and is deemed by the investigator to be deriving benefit from elotuzumab and/or other study drugs as defined by the previous protocol
Previous neurosurgery on the brain
Previous scar or mesh at the level of ileal conduit
Participated during a previous admission
Subjects who have had previous chemotherapy exposure
Previous treatment with low level laser (regardless of indication)
Previous participation in GCRA
Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter study
PATIENT: Informed of diagnosis of incurable disease within the previous 8 weeks
Previous antiangiogenic therapy
Previous, preoperative celiac nerve block
History of Guillain-Barre within 6 weeks of previous influenza vaccination
Known previous treatment failure to erythropoiesis stimulating agents (ESAs) (eg, rHuEPO, darbepoetin alfa).
Previous intrapleural therapy for MPE on the same side
Previous acupuncture treatment for any indication within 30 days of enrollment
Previous laser treatment of telangiectasias
Previous radiation to the chest or breast
Previous treatment with topical menthol (menthol/methylsalicylate products like BenGay, Aspercreme, or Icy Hot) of any concentration within the previous 1 month
Previous therapy with urate oxidase
Previous cisplatin treatment
Previous acupuncture treatment for any indication within 30 days of enrollment
Previous genetic testing or counseling regarding cancer risk
Subjects with a previous esophagectomy
Previous radiation to both breasts
Any previous treatment for HCV =< 6 months prior to registration
Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator).
Previous or current treatment with GLP-1 receptor agonists (e.g. exenatide, liraglutide).
Enrolment in a previous study with netupitant (either alone or in combination with palonosetron).
Have had antibiotic therapy, probiotic supplements, or professional cleaning within the previous 3 months
Any adenoma that was not completely removed during previous colonoscopy
Any previous surgical excision of cervical intraepithelial neoplasia (CIN) or hysterectomy
Patient has had previous exposure to Folotyn within 6 months of study enrollment
Previous adverse reactions to smallpox vaccination
Previous ablative therapy for Barrett’s esophagus
Have changed type of hormonal contraception during the previous 8 weeks
Previous treatment wth any TERT or IL-12 containing therapy, or any other DNA immunotherapy;
Subject has had previous radiation exposure of the involved breast
Patient has not received any previous brain RT.
No previous radiotherapy or systemic treatment for SCCHN
Previous partial of total colectomy
Previous treatment with acupuncture in the last 12 months
Has ever participated in a previous study of aprepitant or fosaprepitant or has taken an investigational drug with the last 4 weeks.
Previous diagnosis of CRC
Previous exposure to OTL38
Prior treatment with alpha radiation therapy (Radium Ra 223 chloride; Xofigo™) during the previous 60 days
Patients who have already received tumor treatment (either systemic or loco-regional such as previous Y90RE, microwave or radiofrequency [RF] ablation or transarterial chemoembolization [TACE])
History of previous administration of GBCA
Previous radiation to the breast or axilla
Previous thoracic surgery
Previous exposure to OTL38
Previous systemic or radiation treatment for cancer of any type within 1 year
History of taken antibiotics in the previous 3 months
Have had previous image guided FNAB or surgical biopsy of the target nodule of interest within the 45 days of baseline Imagio Scan;
Previous prostrate surgeries
Previous systemic or radiation treatment for another cancer of any type within the last 2 months
Has received previous treatment with another agent targeting the T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (TIGIT) receptor
Active inflammatory gastrointestinal disease or previous gastric resection or lap band
Patients must have no previous radiation to the abdomen
Has had previous surgery or radiation to node basins that would be involved in the ILM procedure
Cancer survivors who have previous exposure to medications or chemotherapy that cause neuropathy are excluded from this study
Prior treatment with alpha radiation therapy (Radium Ra 223 chloride; Xofigo™) during the previous 60 days
Patient must not have a previous history of laryngeal cancer
Has received previous myeloma-specific therapy.
Previous treatment with BCR-ABL inhibitors other than nilotinib for more than a total cumulative duration of 4 weeks
Previous treatment with alpha-interferon of any duration
Patients must have completed all previous anticancer therapy for at least 2 weeks prior to the first planned dose of omacetaxine, except as noted below, and must have fully recovered from side effects of a previous therapy.
Previous exposure to OTL38
At least 4 weeks since any previous treatment for cancer
Have not recovered to ? Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs)
Previous treatment with poziotinib prior to study participation.
Pomalidomide naive disease
Prior pomalidomide treatment (for patients on the pomalidomide arm)
Females of child bearing potential (FCBP) must have a negative serum or urine pregnancy test prior to start of treatment. Participants must agree to ongoing pregnancy testing. All patients must be willing to comply with all requirements of the USA pomalidomide Risk Evaluation and Mitigation Strategy (REMS) program or the pomalidomide Pregnancy Prevention Plan (PPP).
Prior exposure to pomalidomide
Previous treatment with ixazomib or pomalidomide
Pts who have received prior treatment with pomalidomide (Phase II only)
Medically supervised (ie, performed in a clinic) pregnancy testing, including those who commit to true abstinence. Two pregnancy tests must be conducted prior to starting pomalidomide. The first pregnancy test must be performed 10 to 14 days prior to the start of pomalidomide and the second pregnancy test must be performed within 24 hours prior to starting pomalidomide. Females of childbearing potential with regular or no menstrual cycles must also agree to have pregnancy tests weekly for the first 28 days study participation, every 28 days while on study, at study treatment discontinuation, and at Day 28 following pomalidomide discontinuation. If menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28 days of study participation and then every 14 days while on study, at study treatment discontinuation visit, and at Days 14 and 28 following pomalidomide discontinuation.
All male and female subjects must follow all requirements defined in the pomalidomide Pregnancy Prevention Program.
Must be willing and able to adhere to pomalidomide-related risk mitigation activities if randomized to the pomalidomide+dexamethasone (pom+dex) arm (e.g., Risk Evaluation and Mitigation Strategies [REMS], pregnancy prevention programs).
Prior exposure to elotuzumab or pomalidomide
Any prior use of pomalidomide
Prior therapy with pomalidomide
History of treatment with venetoclax or another B-Cell Lymphoma (BCL)-2 inhibitor or pomalidomide.
Prior treatment with pomalidomide
Prior exposure to pomalidomide or HDAC inhibitors is allowed
Patients unable to receive adequate thromboprophylaxis in combination with pomalidomide
Patients that have previously progressed on pomalidomide treatment
Has received previous therapy with pomalidomide
Prior treatment with pomalidomide
Has received previous therapy with pomalidomide and did not achieve at least a stable disease
May have undergone prior treatment with pomalidomide if patient is not refractory to pomalidomide and has previously achieved a response of MR or better to pomalidomide.
Prior therapy with pomalidomide with best response of PD or SD.
Must be Pomalidomide naïve.
Prior therapy with pomalidomide.
Previous treatment with pomalidomide
Prior therapy with a combination regimen containing pomalidomide except the 2 drug combination of pomalidomide and dexamethasone
Patients who are pomalidomide refractory, defined as patients who progress on or within 60 days of pomalidomide when given as a single agent or with dexamethasone
Patients who are receiving any other investigational agents or who have received pomalidomide in the past
Prior treatment of any duration with pomalidomide
Any prior use of thalidomide or pomalidomide
Previous therapy with pomalidomide.
Prior exposure to pomalidomide for subjects enrolling in the pomalidomide/dexamethasone combination arm.
No prior therapy with pomalidomide or everolimus
Prior pomalidomide exposure
Males must also agree to refrain from donating semen or sperm while on pomalidomide and for 28 days after discontinuation from this study
Previous therapy with Pomalidomide
A minimum of 2 prior lines of therapy including an IMiD and a PI and is refractory to pomalidomide and/or daratumumab
Previous enrollment in the present study
Previous randomization in the present study
Previous enrollment in the present study
Previous enrollment in the present study
Previous enrollment in the present study
Previous enrolment in the present study.
Previous enrollment in the present study
Previous enrollment in the present study
Previous enrollment or randomization in the present study.
Previous enrollment in the present study
Previous enrollment in the present study
Previous enrolment in the present study
Previous enrollment or randomization in the present study.
Previous enrolment in the present study
Previous enrolment in the present study
Previous enrollment in the present study
Previous enrollment or randomization in the present study
Previous enrollment in this study
Previous enrollment in the present study
Previous enrollment in the present study
Previous enrollment or randomization in this study
Previous enrollment (or assignment) in the present study
Previous enrollment in the present study.
Previous enrollment in the present study
Previous treatment in the present study.
Previous enrollment in the present study.
Previous enrollment in the present study
Previous enrollment in the present study;
Previous enrollment in the present study
Previous enrollment in the present study
Present for CNB
Previous enrollment in the present study
Previous enrollment or randomization of treatment in the present study
